This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D48 (Neoplasm of uncertain or unknown behavior of other and unspecified sites) | Special Copayment Reduction: V193 (cancer special copayment reduction: 5% copayment for 5 years from the registration date) |
| B. Synonyms | Borderline tumor, intermediate neoplasm, tumor of indeterminate behavior, low malignant potential tumor |
| C. Adult onset | Found mainly in adults from middle age onward; because histologic findings lie between benign and malignant, the clinical course is difficult to predict and long-term follow-up is essential. |
| 1. History | The concept of borderline tumors emerged in the early 20th century as advances in pathology revealed the limits of the dichotomous benign/malignant classification system. |
| 2. Causes | Multiple factors are involved, including gene mutations, exposure to radiation and carcinogens, chronic inflammation, and immunodeficiency. |
| 3. Genetics | Varies by site, but partial alterations of tumor suppressor genes and oncogenes such as KRAS, PIK3CA, and TP53 are observed. |
| 4. General epidemiology | Accounts for about 5–10% of all neoplasms, and incidence varies greatly by site. Borderline tumors of ovarian origin are relatively more common in women. |
| 5. Pathophysiology | Has an intermediate pathophysiology in which only some steps of malignant transformation have progressed, such as abnormal cell cycle regulation, induction of angiogenesis, and proliferation without local invasion. |
| 6. Symptoms | Varies by site of origin; compressive symptoms from increasing tumor size, functional abnormalities, or incidental discovery without symptoms are common. |
| 7. Signs | Physical examination findings such as a palpable mass, lymphadenopathy, and decreased organ function may be present. |
| 8. Screening | Follow-up with regular imaging (ultrasound, CT, MRI) and measurement of serum tumor markers is the main screening strategy. |
| 9. Diagnosis | Histopathological examination by tissue biopsy is essential, with final classification by molecular pathology testing. |
| 10. Treatment | Surgical resection is the primary treatment, and adjuvant treatment is determined according to the site and extent of resection. |
| 11. Prognosis | Mostly favorable with complete resection, but recurrence and malignant transformation are possible depending on site and histologic features, so long-term follow-up is needed. |
| 12. Prevention | Avoidance of carcinogenic risk factors, regular checkups, and early detection through counseling of genetically high-risk groups are important. |
| 13. References | WHO Classification of Tumours Editorial Board. Classification of Tumours: Soft Tissue and Bone Tumours. 5th ed. IARC; 2020 … and 9 other papers |
The concept of a neoplasm of uncertain or unknown behaviour took shape alongside the remarkable advances in pathology in the early 20th century. Until the late 19th century, the prevailing system simply divided tumors into benign and malignant, but with the refinement of microscopy and cellular pathology, various groups of tumors lying between the two categories gradually began to be discovered. In the 1950s, researchers continuing the cellular pathology tradition of Rudolf Virchow reported cases of tumors that had histologically benign features yet caused local recurrence or distant metastasis during their clinical course, and as a result, the limitations of the simple dichotomy began to be formally acknowledged.
The World Health Organization (WHO) first introduced the 'uncertain behaviour' category into the International Classification of Diseases (ICD) in 1956, and after several revisions it was established as the current ICD-10 D37–D48 code system. In particular, serous borderline tumor of the ovary was first recognized as an independent diagnostic category in the 1973 WHO classification, which led to the concept of 'borderline malignancy' being formally described in pathology textbooks. In the 1980s, various intermediate neoplasms in soft tissue tumors, such as DFSP (dermatofibrosarcoma protuberans) and hemangiopericytoma, also began to be described.
Since the 1990s, when the era of molecular pathology began, advances in genomic analysis technology have revealed the molecular genetic features of tumors of uncertain behavior; some have been reclassified into separate diagnostic categories, while others still remain within the D48 group. Since the 2000s, the list of tumors in this category has been finely adjusted with each revision of the volumes of the WHO tumor classification (Blue Book series); in particular, the 2020 WHO 5th edition classification added new intermediate tumor categories or reclassified existing tumors in several fields, including soft tissue and bone tumors and central nervous system tumors. Within this classification system, D48 functions as a residual category in the D37–D48 group that collectively codes neoplasms of uncertain behavior arising in other and unspecified sites outside specific sites such as the ovary and placenta.
The causes of D48 neoplasms vary greatly with the site of origin and histologic type, but DNA damage to cells and partial defects in tumor suppressor mechanisms are commonly involved. The best-known risk factor is exposure to ionizing radiation; in patients with a history of radiation therapy, the risk of developing borderline tumors in the skin, soft tissue, bone, and elsewhere increases significantly. Chemical carcinogens (benzene, polycyclic aromatic hydrocarbons, etc.) and some occupational exposures have also been reported to be associated with intermediate neoplasms of soft tissue and internal organs.
Chronic inflammation is another important etiologic factor. Oxidative stress, excess cytokines, and abnormal cell proliferation arising during repeated tissue injury and regeneration contribute to the conversion of normal cells to a premalignant state. Representative examples are the relationship between Helicobacter pylori infection and gastrointestinal borderline tumors, and between human papillomavirus (HPV) and borderline lesions of the cervix. The incidence of neoplasms of uncertain behavior is also known to increase in immunosuppressed states (taking immunosuppressants after organ transplantation, HIV infection, etc.).
Hormonal factors also play an important role in some borderline tumors. Borderline tumors of ovarian origin correlate with the number of ovulations, and the risk is reported to be higher in nulliparous women or women who have used ovulation-inducing agents for a long time. Genetic predisposition cannot be ignored either: BRCA1/2 mutation carriers have an increased risk of both ovarian borderline and malignant tumors. Obesity, smoking, and advanced age act as nonspecific risk factors associated with the development of borderline tumors at various sites.
The genetic background of neoplasms of uncertain behavior classified under D48 shows considerable heterogeneity depending on the site of origin and histologic type. In serous borderline tumors of ovarian origin, activating mutations of the KRAS and BRAF genes are detected in 50–70%, which is understood as the molecular basis for local proliferation without complete malignant transformation. In mucinous borderline tumors, the KRAS mutation rate is even higher, found in about 80% or more.
Intermediate tumors of soft tissue origin characteristically show various chromosomal translocations and fusion genes. For example, dermatofibrosarcoma protuberans (DFSP) is characterized by the COL1A1-PDGFB fusion gene resulting from the t(17;22)(q22;q13) translocation, and the resulting PDGF receptor overactivation promotes cell proliferation. In hemangiopericytoma, the NAB2-STAT6 fusion gene has been reported.
In intermediate tumors of skin origin, TP53 mutations, CDKN2A (p16) deletion, and telomere shortening are observed, and these changes are associated with mechanisms for evading cellular senescence. However, unlike fully malignant tumors, loss of E-cadherin or overexpression of basement membrane-degrading enzymes (MMPs), which enable metastasis, is relatively rare. With the introduction of next-generation sequencing (NGS), the somatic mutation profiles of tumors in the D48 group are gradually being revealed, and this is expected to contribute to reclassification based on molecular targets and to the development of personalized treatment strategies.
Neoplasms of uncertain behavior are estimated to account for about 5–10% of all neoplasms, but the exact incidence varies by country depending on diagnostic criteria and pathology reporting systems. According to data from the Korea Central Cancer Registry, annual registrations in the D37–D48 group (all neoplasms of uncertain behavior) number in the thousands, and the proportion accounted for by D48 differs depending on the reporting year and diagnostic method.
Sex distribution varies by tumor type. Ovarian borderline tumors occur exclusively in women and predominantly in their 40s to 60s, while soft tissue intermediate tumors show no great difference in the male-to-female ratio but are somewhat more common in middle age. Borderline tumors of skin origin (e.g., atypical fibroxanthoma) are more frequent in elderly men and occur mainly on sun-exposed areas. Intermediate tumors of bone origin are also not uncommonly observed in adolescents and young adults.
Regarding geographic distribution, ovarian borderline tumors have a relatively high incidence in developed Western countries, which is presumed to be associated with delayed age at first childbirth and declining birth rates. In contrast, there is no clear regional bias in the occurrence of soft tissue intermediate tumors. Overall, the incidence of D48 neoplasms is on the rise with the transition to an aging society, and increased diagnosis due to advances in precision imaging and pathology testing also contributes in part.
Unlike fully malignant tumors, the pathogenesis of neoplasms of uncertain behavior can be understood as an 'intermediate state' in which only some steps of cell cycle dysregulation have progressed. The conversion from normal cells to neoplastic cells is a multistep process (multistep carcinogenesis) that passes through the stages of initiation, promotion, and progression. D48 neoplasms correspond to a state that has stalled without reaching the progression stage of this process; as a result, local proliferation is possible, but the capacity for vascular and lymphatic invasion and distant metastasis is limited.
In terms of cell proliferation, overexpression of growth factor receptors (EGFR, PDGFR, FGFR, etc.) or constitutive activation of downstream signaling pathways (RAS-MAPK, PI3K-AKT) is characteristically observed. These signaling abnormalities promote cell division, but because the p53 and Rb pathways partially retain function, they do not reach unrestrained cell cycle progression. In terms of resistance to cell death, upregulation of BCL-2 family anti-apoptotic proteins is observed, but the caspase activation pathway is preserved.
In terms of angiogenesis as well, intermediate tumors show lower levels of VEGF expression and form incomplete vascular networks compared with fully malignant tumors. This can act as a factor making it difficult for the tumor to grow beyond a certain size. In terms of the tumor microenvironment, immune cell infiltration (T cells, NK cells) is relatively more active than in fully malignant tumors, and immune surveillance mechanisms are presumed to contribute to suppressing tumor progression. However, malignant transformation can occur with certain environmental stimuli or additional genetic damage, so continued follow-up is needed.
Symptoms of D48 neoplasms vary greatly with the site of origin, and the absence of specific symptoms is also common. Intra-abdominal tumors (e.g., ovarian borderline tumors) begin with nonspecific symptoms such as abdominal bloating, lower abdominal discomfort or dull pain, and indigestion, and symptoms often appear only after the tumor has grown to a considerable size. Some patients may have ascites, in which case abdominal distension becomes the main complaint.
Intermediate tumors of soft tissue origin are most often first discovered as a slowly growing painless mass. When the tumor begins to compress nerves, blood vessels, or adjacent structures, local pain, paresthesia, and numbness may occur. Borderline tumors arising in the skin commonly present with dermatologic symptoms, accompanied by ulceration or causing changes in skin color. Intermediate tumors of bone origin are sometimes first discovered when a pathological fracture occurs, along with persistent dull pain in the affected area.
Neoplasms of uncertain behavior arising in endocrine organs (e.g., of adrenal, pituitary, or pancreatic endocrine origin) can cause specific symptoms due to hormone hypersecretion. For example, an adrenal tumor of uncertain behavior may show Cushing syndrome-like symptoms such as elevated blood pressure, weight gain, and muscle weakness, or may cause sweating, palpitations, and paroxysmal hypertension in a pattern resembling pheochromocytoma. Systemic symptoms may include fatigue, loss of appetite, and unexplained weight loss, which are related to the metabolic activity of the tumor itself or cytokine secretion.
Signs found on physical examination depend on the location and size of the tumor. In intra-abdominal borderline tumors, a relatively well-demarcated mass may be palpable in the lower or upper abdomen on abdominal palpation, and when ascites is present, shifting dullness and fluid thrill are observed. On gynecologic examination, it is palpated as an adnexal mass, and in some cases appears adherent to the uterus.
Soft tissue intermediate tumors are palpated as firm or rubbery masses in the skin or deep soft tissue. The mass is often relatively well-demarcated and mobile, but mobility is limited when it is deep or fixed to the fascia. Cervical lymphadenopathy or distant masses suggest metastasis and must be evaluated, but true lymph node metastasis is rare in D48 neoplasms. Borderline tumors of skin origin may show skin signs such as uneven changes in skin color, border irregularity, and satellite nodules.
Some specific findings may also be observed on blood tests. In borderline tumors, serum tumor markers such as CA-125 may be mildly elevated, but often at lower levels than in fully malignant tumors. In adrenal tumors of uncertain behavior, abnormal blood cortisol, catecholamine, and aldosterone levels suggest endocrine dysfunction. Elevation of CRP and ESR, indicating a systemic inflammatory response, may be present and correlates to some degree with tumor size and local invasiveness.
No organized population-based screening program for D48 neoplasms has been standardized to date. However, targeted surveillance of high-risk groups has important clinical significance. For ovarian borderline tumors, transvaginal ultrasound once or twice a year and serum CA-125 measurement are recommended for women who are BRCA1/2 mutation carriers or have a family history.
No specific screening test exists for soft tissue intermediate tumors, and imaging evaluation of suspicious areas by ultrasound or MRI is used as the main diagnostic tool. In high-risk groups for borderline tumors associated with hereditary cancer syndromes (e.g., Li-Fraumeni syndrome, Gardner syndrome, NF1), whole-body MRI and regular skin examinations are sometimes recommended. For borderline tumors of skin origin, a full-body skin examination by a dermatologist is useful in high-risk groups (immunosuppression, chronic sun exposure, history of previous skin tumors).
For clinically incidentally discovered masses (incidentalomas), follow-up or tissue biopsy is decided according to imaging characteristics. In particular, for adrenal incidentaloma, the possibility of a neoplasm of uncertain behavior is assessed by combining size (over 4cm), imaging features (heterogeneity, irregular borders, abnormal CT HU values), and presence of hormonal dysfunction. For gastrointestinal submucosal tumors found during endoscopy, layer-of-origin assessment by endoscopic ultrasound (EUS) and fine-needle aspiration biopsy (FNA) help determine borderline classification.
The definitive diagnosis of D48 neoplasms is made by histopathological examination, which is the most essential diagnostic method. Depending on the location and size of the tumor, an appropriate biopsy method is chosen among image-guided needle biopsy, endoscopic biopsy, excisional biopsy, or incisional biopsy. Because obtaining a sufficient amount of tissue increases the accuracy of pathological interpretation, core needle biopsy or excisional biopsy is recommended whenever possible.
Histopathological evaluation comprehensively analyzes cellular atypia, mitotic count, presence of necrosis, vascular invasion, and basement membrane disruption. Immunohistochemistry (IHC) staining is essential for identifying the cell of origin of the tumor and semiquantitatively assessing malignancy markers (e.g., Ki-67, p53, CD34, S-100). Molecular pathology testing identifies specific gene mutations and chromosomal abnormalities through FISH (fluorescence in situ hybridization), PCR, next-generation sequencing (NGS), and others.
Imaging is used to evaluate tumor size, location, relationship with surrounding structures, and presence of distant metastasis. CT is useful for determining tumor extent and checking for intra-abdominal spread, and MRI, with its high soft tissue resolution, is better suited for evaluating the internal structure of the tumor and neurovascular involvement. PET-CT generally shows low metabolic activity in neoplasms of uncertain behavior, but when malignant transformation is suspected, it can be used as an adjunct to assess the degree of FDG uptake in the lesion. Serum tumor markers (CA-125, CEA, AFP, LDH, S-100, chromogranin A, etc.) have low specificity but are useful as follow-up indicators.
The primary treatment of D48 neoplasms is complete surgical resection. Because completeness of resection has the greatest impact on recurrence rate and prognosis, the principle is to secure as adequate a resection margin as possible. Depending on tumor location and anatomical relationships, various methods are applied, including open surgery, laparoscopic surgery, and endoscopic resection. For ovarian borderline tumors in women of reproductive age, fertility-sparing surgery may be considered, but in this case the somewhat increased risk of recurrence must be fully discussed with the patient.
Postoperative adjuvant therapy is generally not recommended as standard for D48 neoplasms. In completely resected ovarian borderline tumors, the benefit of adjuvant chemotherapy has not been established and may instead cause unnecessary toxicity. However, in cases of incomplete resection or when surgery is not possible, and when malignant transformation is histologically confirmed, site-specific standard chemotherapy or radiation therapy is considered. In some intermediate soft tissue tumors such as DFSP, molecular targeted agents such as imatinib are used for preoperative tumor reduction or for treatment of unresectable cases.
Radiation therapy may be given as an adjunct when surgical margins are positive (positive margin) or re-resection is not possible. In particular, for intermediate tumors in anatomically difficult-to-resect areas such as the head and neck and paraspinal regions, radiation therapy can contribute to local control. As systemic therapy, the role of immune checkpoint inhibitors and angiogenesis inhibitors is being explored in some D48 tumors but has not yet been established as standard therapy. Follow-up with regular imaging and clinical evaluation is recommended for at least 5 years after surgery, and for 10 years or more in some groups at high risk of recurrence.
The prognosis of D48 neoplasms is generally favorable compared with fully malignant neoplasms but differs considerably by site of origin and histologic subtype. The 5-year survival of completely resected ovarian borderline tumors is very favorable at over 95%, and 10-year survival also remains at 80–90%. However, recurrence can occur in about 10–15% even after complete resection, and rarely full malignant transformation occurs. Because recurrence may appear several years after surgery, long-term follow-up is essential.
Among soft tissue intermediate tumors, DFSP has a local recurrence rate of less than 2% with complete resection but a recurrence rate as high as 30–50% with incomplete resection. Distant metastasis is extremely rare in DFSP, at less than 1%. Atypical lipomatous tumor/well-differentiated liposarcoma has a high recurrence rate when arising in the retroperitoneum, where complete resection is difficult, and carries a risk of malignant transformation to dedifferentiation, so its prognosis is relatively poor. Important prognostic factors include completeness of initial resection, tumor size, histologic grade, and molecular biological features.
When recurrence is confirmed during follow-up, prognosis is determined by whether the recurrent lesion is resectable. Reoperation for local recurrence can in most cases be expected to achieve cure or long-term remission, but prognosis becomes markedly poor when peritoneal dissemination or distant metastasis is present. Prognosis after malignant transformation depends on the type and stage of the resulting malignant tumor, but treatment response generally tends to be poorer than for primary malignant tumors.
No specific prevention for D48 neoplasms has yet been established, but the risk of development can be lowered by controlling known risk factors. Minimizing radiation exposure is important: appropriate dose management (ALARA principle) should be followed for medical radiological examinations, and patients who have received radiation therapy in the past should receive regular follow-up of the treated area. Occupational carcinogen exposure (benzene, asbestos, aromatic amines, etc.) should be reduced by wearing appropriate protective equipment and improving the work environment.
Because smoking and excessive alcohol consumption increase the risk of neoplasms at many sites, smoking cessation and moderation of drinking are recommended. Obesity can raise the risk of borderline tumors through chronic low-grade inflammation and hormonal imbalance, so maintaining a normal body weight is important. Regular physical activity contributes to enhancing immune function and maintaining metabolic health, helping to prevent neoplasms. Healthy eating habits (increased intake of vegetables, fruits, and whole grains; reduced processed meat and high-fat foods) are also recommended.
In high-risk groups with hereditary cancer syndromes (BRCA mutations, Lynch syndrome, Li-Fraumeni syndrome, NF1, etc.), genetic counseling and risk-reducing surgery may be considered. In particular, risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers is known to greatly lower the risk of both ovarian borderline and malignant tumors. Oral contraceptive use reduces the risk of ovarian borderline tumors by reducing the number of ovulations. Early detection through regular health checkups and prompt specialist care when abnormal findings arise is the best preventive strategy.
WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. 5th ed. International Agency for Research on Cancer (IARC). 2020. ISBN: 978-92-832-4502-5.
Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31(5):539-557. DOI: 10.1053/hp.2000.6745. PMID: 10836293.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. DOI: 10.1016/j.cell.2011.02.013. PMID: 21376230.
Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med. 2006;130(10):1448-1453. DOI: 10.5858/2006-130-1448-GOSTSR. PMID: 17090186.
Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22(5):576-587. DOI: 10.1097/00000478-199805000-00009. PMID: 9591728.
Longacre TA, McKenney JK, Tazelaar HD, Hendrickson MR, Kempson RL. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol. 2005;29(6):707-723. DOI: 10.1097/01.pas.0000164030.82810.db. PMID: 15897738.
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds). WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. IARC Press. 2013. ISBN: 978-92-832-2434-1.
Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973-983. DOI: 10.1016/S0140-6736(13)60106-3. PMID: 23623056.
Kim YH, Kim SM, Lim DH. Characteristics and outcomes of patients with neoplasm of uncertain behaviour: a Korean single-center experience. J Korean Med Sci. 2019;34(22):e166. DOI: 10.3346/jkms.2019.34.e166. PMID: 31172712.
Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. 6th ed. Mosby/Elsevier. 2014. ISBN: 978-0-323-08834-3.